Terbutaline Monograph: Beta-2 Agonism, Bronchospasm and Prolonged Tocolysis Warning

Evidence-informed pharmacology monograph. Reviewed 10 November 2026. Educational material only; clinical use requires current local product labeling and patient-specific assessment.

Overview and chemical correction

Terbutaline is a selective short-acting beta-2 adrenoceptor agonist (SABA) used for prevention and reversal of bronchospasm in authorized formulations. It is a resorcinol-type phenylethanolamine, not the pyrrole-based molecule or classic catechol derivative incorrectly described in the original article. Its clinical role depends strongly on the route and national product labeling [1,2].

Receptor mechanism

Beta-2 adrenoceptors couple to Gs, increasing adenylyl cyclase activity, intracellular cAMP and protein kinase A signaling. In airway smooth muscle these effects decrease contractility and promote bronchodilation. Beta-2 stimulation can also reduce uterine smooth-muscle tone, but that physiologic effect does not establish safety for sustained suppression of preterm labour [1].

Approved respiratory indications and delivery

US subcutaneous terbutaline injection is indicated for prevention/reversal of bronchospasm in patients aged 12 years or older with asthma and reversible bronchospasm associated with bronchitis/emphysema; inhaled/oral availability and indications vary internationally. Frequent need for rescue medication signals worsening asthma and a need to reassess anti-inflammatory treatment, not simply escalate SABA exposure. In contemporary asthma care, ICS-containing regimens are essential for exacerbation prevention [1,3].

FDA boxed warning: prolonged tocolysis

The US terbutaline injection boxed warning states it has not been approved for and must not be used for prolonged tocolysis beyond 48–72 hours, especially not maintenance treatment in outpatient or home settings. Serious maternal reactions, including death, have occurred. Risks include tachycardia, arrhythmias, pulmonary edema, myocardial ischemia, hyperglycemia and hypokalemia; fetal tachycardia and neonatal hypoglycemia can occur. Any obstetric use must be an individualized, tightly monitored specialist decision under local protocol, not routine chronic therapy [2].

Pharmacokinetics and adverse effects

After subcutaneous administration, terbutaline is systemically absorbed; metabolism includes sulfate conjugation and substantial elimination occurs through urine. Renal dysfunction can alter exposure. Common beta-agonist effects include tremor, palpitations, tachycardia, headache and anxiety. High doses can lower serum potassium, elevate glucose and trigger dysrhythmias; significant cardiovascular disease and thyrotoxicosis require caution [1,2].

Interactions and patient safety

Nonselective beta blockers may antagonize bronchodilation and aggravate bronchospasm. Other sympathomimetics, certain antidepressants and methylxanthines can increase cardiovascular effects. Monitor pulse, BP, potassium and glucose when clinically relevant. The drug is a bronchodilator and must not be marketed as an approved long-term outpatient preterm-labour treatment [2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. DailyMed. Terbutaline sulfate injection: US prescribing information, boxed warning regarding prolonged tocolysis, updated October 2024. Available from: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d79e3a0-a83e-4406-b792-99857ba91840
  3. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2025 update. Available from: https://ginasthma.org/wp-content/uploads/2025/11/GINA-2025-Update-25_11_08-WMS.pdf
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *